Patients Paying For Remicade May Have Been Overcharged E-mail
October 11, 2017

A recently filed lawsuit by a competing manufacturer alleges that Johnson & Johnson, the manufacturer of Remicade, engaged in a scheme to ensure that similar, lower priced drugs would not become viable competitors.  

Consumers purchasing Remicade, a drug used to treat rheumatoid arthritis, may have paid too much for the product.  A recently filed lawsuit by a competing manufacturer alleges that Johnson & Johnson, the manufacturer of Remicade, engaged in a scheme to ensure that similar, lower priced drugs would not become viable competitors.  Thus, according to the lawsuit, Johnson & Johnson was able to shield Remicade from competition, resulting in higher prices for the drug.  The suit further alleges that this conduct violated the antitrust laws.

If you or someone you know may have been impacted by these allegations, please contact Finkelstein Thompson LLP at  This email address is being protected from spam bots, you need Javascript enabled to view it or call us toll-free at 1-877-337-8000.

This email address is being protected from spam bots, you need Javascript enabled to view it